Convalescent plasma therapy emerged as an early experimental therapy for the treatment of Covid-19. However, despite limited data regarding its safety and efficacy, the therapy was extensively publicised by multiple politicians as a cure. We analyse the impact of this political narrative around medical therapeutics on the pandemic using the coherentist model of public health ethics. The clinical benefits of the therapy are evaluated in terms of reduction in mortality and disease progression as compared to the potential transfusion-related adverse events. Political advocacy of therapeutics might hamper the autonomy and decision-making of individuals and institutions. Marketing and monetisation of convalescent plasma might cause inequitable distribution and unregulated use. It also creates an economic burden on the government and healthcare which should be justified by the additional cost/effectiveness ratio of the therapy. This article exemplifies the inadvertent effects and ethical challenges following political narratives about medical therapeutics and the importance of involving ethics in designing policies concerning public healthcare.